UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

Frontiers in medicine, 2021-05, Vol.8, p.670526

Mahlangu, Johnny N

2021

Volltextzugriff (PDF)

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

The New England journal of medicine, 2013-12, Vol.369 (24), p.2313-2323

2013

Volltextzugriff (PDF)

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing

The Lancet (British edition), 2021-02, Vol.397 (10274), p.630-640

2021

Volltextzugriff (PDF)

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Research and practice in thrombosis and haemostasis, 2022-07, Vol.6 (5), p.e12760-n/a, Article e12760

2022

Volltextzugriff (PDF)

Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa

PloS one, 2018-10, Vol.13 (10), p.e0204899-e0204899

2018

Volltextzugriff (PDF)

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

The New England journal of medicine, 2017-08, Vol.377 (9), p.809-818

2017

Volltextzugriff (PDF)

Requirements to participate in haemophilia clinical trials

Haemophilia : the official journal of the World Federation of Hemophilia, 2020-04, Vol.26 (S3), p.22-25

Mahlangu, Johnny N.

2020

Volltextzugriff (PDF)

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2018-12, Vol.32 (6), p.561-570

Mahlangu, Johnny N.

2018

Volltextzugriff (PDF)

Redefining prophylaxis in the modern era

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-02, Vol.27 (S3), p.21-27

2021

Volltextzugriff (PDF)

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2021-08, Vol.19 (8), p.1883-1887

2021

Volltextzugriff (PDF)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B

Therapeutic Advances in Hematology, 2018-11, Vol.9 (11), p.335-346

Mahlangu, Johnny N.

2018

Volltextzugriff (PDF)

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

British journal of haematology, 2023-01, Vol.200 (2), p.229-239

2023

Volltextzugriff (PDF)

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-01, Vol.25 (1), p.33-44

2019

Volltextzugriff (PDF)

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

Thrombosis and haemostasis, 2016-07, Vol.116 (1), p.1-8

2016

Volltextzugriff (PDF)

Thrombotic thrombocytopenic purpura: A 5‐year tertiary care centre experience

Journal of clinical apheresis, 2019-02, Vol.34 (1), p.44-50

2019

Volltextzugriff (PDF)

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Journal of thrombosis and haemostasis, 2021-01, Vol.19 (S1), p.32-41

2021

Volltextzugriff (PDF)

Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-05, Vol.27 (3), p.398-407

2021

Volltextzugriff (PDF)

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

Journal of thrombosis and haemostasis, 2021-01, Vol.19 (S1), p.21-31

2021

Volltextzugriff (PDF)

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-11, Vol.27 (6), p.e772-e775

2021

Volltextzugriff (PDF)

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-03, Vol.27 (2), p.221-228

2021

Volltextzugriff (PDF)

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

British journal of haematology, 2015-01, Vol.168 (1), p.124-134

2015

Volltextzugriff (PDF)

Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing

Clinical laboratory (Heidelberg), 2019-01, Vol.65 (4/2019)

2019

Volltextzugriff (PDF)

Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa

International journal of nephrology and renovascular disease, 2019-01, Vol.12, p.19-32

2019

Volltextzugriff (PDF)

Treatment with Marstacimab for People with Severe Hemophilia a or B: a Plain Language Summary of the results from a short-term study and a longer-term study

Future Rare Diseases, 2023-12, Vol.3 (4)

2023

Volltextzugriff (PDF)

Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing “Empty Viral Particles” on Safety and Efficacy of Gene Transfer

Blood, 2018-11, Vol.132 (Supplement 1), p.491-491

2018

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(46)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

Utility of reticulocyte haemoglobin content and percentage hypochromic red cells as markers of iron deficiency anaemia among black CKD patients in South Africa

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Requirements to participate in haemophilia clinical trials

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

Redefining prophylaxis in the modern era

A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B

A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia

The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A

Thrombotic thrombocytopenic purpura: A 5‐year tertiary care centre experience

Application of a hemophilia mortality framework to the Emicizumab Global Safety Database

Health‐related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors—A non‐interventional study

Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database

Patient preference for emicizumab versus prior factor therapy in people with haemophilia A: Results from the HAVEN 3 and HAVEN 4 studies

Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study

Analytical Performance of a New Immunoturbidimetric Assay for von Willebrand Factor (VWF) Activity Testing

Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa

Treatment with Marstacimab for People with Severe Hemophilia a or B: a Plain Language Summary of the results from a short-term study and a longer-term study

Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing “Empty Viral Particles” on Safety and Efficacy of Gene Transfer

Suchergebnisse filtern